CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway in Boston
The first in-human in vivo clinical trial using CRISPR-Cas9 is now open for enrollment; we take a closer look at this genome editing technology to…
BioAgilytix Team Q&A: Meet Janett Schwarz, Principal Investigator at BioAgilytix
In our latest Team Q&A, we talk to Janett Schwarz, Principal Investigator at BioAgilytix’s European headquarters, about how her role has evolved since joining our…
Event Line-Up: The Bioanalytical Industry Forums We’ll Be at This Fall
We're looking forward to participating in several upcoming bioanalytical conferences and events this fall, ranging from small-circle workshops to global, world-renowned industry forums.
BioAgilytix Team Q&A: Meet Eric Nesbit, Bioanalytical Project Manager/Scientist III
In this Q&A session we talk with Eric Nesbit, Bioanalytical Project Manager/Scientist III at BioAgilytix, to learn more about what led him to leave his…
Meet Jelle Hempenius, Business Development Director, Europe
Did you know that BioAgilytix’s ‘deep bench’ extends beyond those we have working in the lab? Many individuals in our operational departments, from business development…
Gene Therapy Trends: Conditional Approval of Zynteglo Brings Ex Vivo Gene Therapy Into Focus
The recent approval of Zynteglo further builds credibility to the specific and emerging class of cell therapies engineered via “ex vivo” gene therapy. We explain…
C-Path “Points to Consider Document” Clarifies Bioanalytical Assay Validation in Support of Clinical Biomarker Qualification
A contributing author to the Critical Path Institute (C-Path)’s “Points to Consider Document,” Dr. Afshin Safavi summarizes considerations outlined in the paper designed to establish…
Platform Spotlight: ImmunoCAP to Support Diagnosis of Allergic Reactions Against Biologics
The observation of drug-specific IgE antibodies which may cause anaphylaxis prompts the need to test for these antibodies - but because IgE are 2000-fold less…
Immunogenicity Assessment Using the Biacore™ T200 SPR System
What are the advantages of using the Biacore™ T200 SPR System for immunogenicity assessments with a tiered approach? Our experts discuss.
510K Approved Assays vs. RUO Assays: Which Best Support Clinical Trial Biomarker Studies?
The answer to the question is “it depends”. Commonly a combination of 510K approved kits (in Europe known as assays that need to follow IVD-directive…